Evidence map›Paper›PMID 36183137›Full record

ArticleBioData mining2022

EZCancerTarget: an open-access drug repurposing and data-collection tool to enhance target validation and optimize international research efforts against highly progressive cancers.

David Dora, Timea Dora, Gabor Szegvari, Csongor Gerdán, Zoltan Lohinai

Open access · goldAbstract read
In one paragraph

Article in BioData mining, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

David DoraDepartment of Anatomy, Histology, and Embryology, Semmelweis University, Tuzolto st. 58, Budapest, 1094, Hungary. dora.david@med.semmelweis-univ.hu.ORCID http://orcid.org/0000-0002-3138-8816
Timea DoraDepartment of Management and Business Economics, Budapest University of Technology and Economics, Budapest, Hungary.
Gabor SzegvariTranslational Medicine Institute, Semmelweis University, Budapest, Hungary.
Csongor GerdánNational Korányi Institute of Pulmonology, Piheno ut 1., 1121, Budapest, Hungary.
Zoltan LohinaiTranslational Medicine Institute, Semmelweis University, Budapest, Hungary. zoltan.lohinai@koranyi.hu.
Semmelweis University · HUBudapest University of Technology and Economics · HUInstitute of Molecular Life Sciences · HU

Funding

Hungarian Scientific Research Fund #124652Hungarian Scientific Research Fund #128666Hungarian Scientific Research Fund #129664
6 · The paper itself

Abstract

The expanding body of potential therapeutic targets requires easily accessible, structured, and transparent real-time interpretation of molecular data. Open-access genomic, proteomic and drug-repurposing databases transformed the landscape of cancer research, but most of them are difficult and time-consuming for casual users. Furthermore, to conduct systematic searches and data retrieval on multiple targets, researchers need the help of an expert bioinformatician, who is not always readily available for smaller research teams. We invite research teams to join and aim to enhance the cooperative work of more experienced groups to harmonize international efforts to overcome devastating malignancies. Here, we integrate available fundamental data and present a novel, open access, data-aggregating, drug repurposing platform, deriving our searches from the entries of Clue.io. We show how we integrated our previous expertise in small-cell lung cancer (SCLC) to initiate a new platform to overcome highly progressive cancers such as triple-negative breast and pancreatic cancer with data-aggregating approaches. Through the front end, the current content of the platform can be further expanded or replaced and users can create their drug-target list to select the clinically most relevant targets for further functional validation assays or drug trials. EZCancerTarget integrates searches from publicly available databases, such as PubChem, DrugBank, PubMed, and EMA, citing up-to-date and relevant literature of every target. Moreover, information on compounds is complemented with biological background information on eligible targets using entities like UniProt, String, and GeneCards, presenting relevant pathways, molecular- and biological function and subcellular localizations of these molecules. Cancer drug discovery requires a convergence of complex, often disparate fields. We present a simple, transparent, and user-friendly drug repurposing software to facilitate the efforts of research groups in the field of cancer research.

Indexed as

Cancer researchData miningDrug databaseDrug-repurposingLung cancer

Identifiers

PMID36183137
PMCPMC9526900
OpenAlexW4298393585

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.